NCT07520916 The Effect of Mobile-Based Perioperative Education on Urinary Incontinence and Erectile Function After Radical Prostatectomy
| NCT ID | NCT07520916 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Giresun University |
| Condition | Prostate Cancer (Post Prostatectomy) |
| Study Type | INTERVENTIONAL |
| Enrollment | 78 participants |
| Start Date | 2026-04-02 |
| Primary Completion | 2027-04-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 78 participants in total. It began in 2026-04-02 with a primary completion date of 2027-04-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective randomized controlled study aims to evaluate the effect of mobile-based perioperative education on postoperative urinary incontinence and erectile function in patients undergoing radical prostatectomy. Patients scheduled for radical prostatectomy will be assigned to either an intervention group or a control group. The intervention group will receive standard care plus a structured mobile application-based perioperative education program including video-assisted pelvic floor muscle training, perioperative education modules, reminders, and follow-up components. The control group will receive routine perioperative care and standard patient education. Data will be collected preoperatively, after urinary catheter removal, and at 1 month and 3 months after surgery. The primary outcomes are urinary incontinence and erectile function, assessed using the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), the International Index of Erectile Function-5 (IIEF-5), and a 24-hour pad assessment. Secondary outcomes include lower urinary tract symptoms and disease-specific quality of life assessed by the International Prostate Symptom Score (IPSS), psychological status assessed by the Depression Anxiety Stress Scale-21 (DASS-21), and system usability assessed by the Turkish version of the Computer System Usability Questionnaire-Short Version (T-CSUQ-SV)
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with prostate cancer and scheduled for elective radical prostatectomy (open, laparoscopic, or robotic) * Aged 18 years or older * Planned to undergo surgery at the study center(s) * Able to use a smartphone and having sufficient digital literacy to operate the mobile application * Provided written informed consent after being informed about the study Exclusion Criteria: * Pre-existing urinary incontinence or erectile dysfunction before surgery * Severe cognitive impairment or severe visual or hearing impairment * Previous pelvic radiotherapy or a history of major pelvic surgery * Presence of severe comorbidity or terminal illness that may interfere with adherence to the study protocol * Technological insufficiency preventing the use of the mobile application
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07520916 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer (Post Prostatectomy). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07520916 currently recruiting?
Yes, NCT07520916 is actively recruiting participants. Contact the research team at alkay@outlook.com.tr for enrollment information.
Where is the NCT07520916 trial being conducted?
This trial is being conducted at Giresun, Turkey (Türkiye).
Who is sponsoring the NCT07520916 clinical trial?
NCT07520916 is sponsored by Giresun University. The trial plans to enroll 78 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.